Cancer is malignant desease that causes many deaths worldwide every year, with most deaths occurring in the middle and advanced stages of cancer. Numerous deaths can be avoided by detecting cancer at an early stage, making early diagnosis and timely therapy critical for cancer treatment.Analyses at the level of nucleic acids rather than phenotypes can eliminate various false positive and negative results,and diagnoses can occur at an earlier stage.Many techniques have been developed for this purpose,including capillary electrophoresis (CE),which has the advantages of high-efficiency,high-speed, high-throughput,automation,cleanliness, and versatility, and CE can be conducted on a microscale or coupled with other separation techniques. These advantages afford this technique the ability to meet the future medical requirements that will undoubtedly call for amassing large numbers of samples for analysis, suggesting that CE may become an important tool for providing data in clinical cancer diagnosis and therapy. This review focuses on CE-based nucleic acid detection as it is applied to cancer diagnosis and therapy, and provides an introduction to the drawbacks and future developments of analysis with CE.
Introduction
Cancer is a disease of great concern because it is the second leading cause of death in the world. Although its occurrence is complicated, molecular studies on carcinogenesis have clearly shown that the malignant transformation of normal to cancer cells relies on genetic alterations of a large number of generic tumour suppressor genes or oncogenes. Oncogenomics, a relatively new subfield of genomics proposed to systematically characterize cancer-associated gene mutations, and has been facilitated by the completion of the Human Genome Projects [1] . Pathologists and oncologists now believe that a substantial number of DNA sequence alterations, such as gene 4 field of genetically altered cells and could represent a potential marker for the clonal expansion of premalignant breast cancer cells.
DNA methylation is a fundamental biological mechanism that plays a key role in the epigenetic regulation of gene expression during development of disease. DNA methylation patterns are highly dysregulated in cancer, leading to inactivation of tumour suppressors and activation of oncogenes, thus contributing to tumorigenesis. Therefore, understanding the biological function of DNA methylation will require the development of sensitive analytical methods allowing the detection and quantification of all types of DNA methylation patterns. CE-LIF with a limit of detection for 5-hydroxymethyl-2'-deoxycytidine (5 hmdC) of 0.45 amol, which is equivalent to approximately to one 5 hmdC per 4,000 normal nucleotides (0.025%) using 1 µg of DNA as the matrix, could be analysed in one run for both the methylation and hydroxymethylation of cytosine [14] . CE-LIF for the quantification of global adenine methylation in DNA, which yielded a limit of detection for N(6)mdA of 280 pM (1.4 amol) ,could also be applied to the analysis of various DNAs [15] . Bisulfite restriction analysis (COBRA)-CE-LIF was used to screen for the degree of DNA methylation in cancer, and the results showed that DNA methylation was eliminated after the cells were treated with an anti-cancer drug (5'-aza-2'-deoxycytidine), suggesting that COBRA-CE-LIF is a potentially useful and cost-effective tool for cancer diagnosis or prognosis based on the heterogeneity of a patient's DNA [16] .A novel bisulfite-microfluidic temperature gradient capillary electrophoresis(bisulfite-µTGCE) platform for gene methylation analysis was developed [17] , that could identify methylated genomic (g) DNA at a detection limit of 7.5pg, and could distinguish a methylation level as low as 0.1%. Methylation-specific PCR-CE [18] was used to investigated the epithelial membrane protein 3(EMP3) promoter hypermethylation status and the results showed that the EMP3 hypermethylation status correlated with 19q13.3 loss and lack of EMP3 expression at protein level. 6 For enhancing the sensitivity of detecting low-level clinically significant cancer-relevant somatic mutations, Warshawsky et al. [21] developed locked nucleic acid PCR-CE to detect FLT3D835/I836 tyrosine kinase domain mutations and insertion mutations in the nucleophosmin 1 gene. Conformation-sensitive capillary electrophoresis (CSCE) for diagnostic mutation scanning with a sensitivity of >99% [22] which was indistinguishable from the sensitivity for conventional sequencing by CE and greatly reduced the number of fragments that need to be sequenced, proved to be a highly sensitive and cost-effective technique suitable for routine genetic diagnostic analysis of heterozygous nucleotide substitutions, small insertions, and deletions.
The For exploring characteristics of DNA damage and TP53 gene mutations in lung cancer, 104
tissue samples from patients with non-small cell lung cancer were studied [25]. These TP53 mutations were detected using denaturant gradient gel electrophoresis (DGGE), automated capillary electrophoresis single-strand conformation polymorphism (SSCP-CE) and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript Yri OE et al.
[31] genotyped patients with Hodgkin lymphoma and healthy controls using CE, relating the risk for Hodgkin lymphoma and outcome of chemotherapy treatment to polymorphisms in genes encoding interleukins and metabolizing enzymes.They found that patients with the UGT1A1 TA tandem repeat TA6/6 genotype had a poorer overall survival, and patients above 40 years with the GSTA1 AA genotype had poorer event-free survival after chemotherapy. In patients above 40 years, the IL-10 rs1800890 T-allele was associated with lower 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript risk for Hodgkin lymphoma. The GSTP1 rs1695 A-allele reduced the risk for HL, and the GSTT1 deleted genotype increased the risk for Hodgkin lymphoma regardless of age.
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Glutathione protects against cancer development by detoxifying carcinogens and free radicals and strengthening the immune system. Recently, a GAG-trinucleotide repeat polymorphism in the 5'-untranslated region of the gene for the rate-limiting enzyme of glutathione biosynthesis, γ-glutamine cysteine ligase (GCL), was shown to be associated with lowered GCL activity and glutathione levels in vitro and in vivo. The GAG repeat genotype was determined using PCR-CE to test the hypothesis that this functional polymorphism in GCL is associated with the risk for lung and aerodigestive tract cancers.The result suggested that glutathione synthesis affected the risk of lung and aerodigestive tract cancers, and further implicated a role for oxidative stress in the development of these cancers [32].
The Human androgen receptor contains a highly polymorphic polyglutamine tract encoded by CAG repeats [(CAG)n] in exon 1 of the androgen receptor gene, which had been reported to be inversely correlated with androgen receptor activity. Fluorescently labelled DNA fragments containing (CAG)n were analysed with PCR-CE, and shorter alleles of the (CAG)n in exon 1 of the androgen receptor gene were found to enhance the susceptibility to polycystic ovary syndrome (PCOS) [33] .
The CYP19 tetranucleotide TTTA repeat polymorphism was genotyped using PCR-CE to evaluate the association between tetranucleotide TTTA repeat polymorphism in the CYP19 gene and polycystic ovary syndrome.The study showed CYP19 tetranucleotide TTTA repeat polymorphism was an ethnic and racial variant and moderately contributed to the pathogenesis of polycystic ovary syndrome in Han Chinese women [34].
Seeking to unravel the molecular biology of a female patient who in 1985 at the age of 55 was diagnosed with a chronic myeloproliferative neoplasm (MPN) and in whom overt acute myeloid leukaemia (AML) developed in 2005, researchers analysed her DNA and RNA using qPCR and PCR-CGE [35]. They found the patient to be positive for the JAK2-V617F mutation throughout the course of disease, whereas a mutation of the nucleophosmin (NPM1) gene emerged at the AML diagnosis and relapse. The 20 year lag between the polycythaemia vera and the AML Page 9 of 37 Analyst   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Detection of cancer biomarkers
The presence of high plasma levels of free-circulating DNA (cfDNA) in lung cancer patients was reported, leading to an interest in using cfDNA as a potential biomarker for early diagnosis Analyst Accepted Manuscript a protein-facilitated affinity CE assay for rapid quantification of miRNA levels in blood serum with a detection limit of 0.5 fM in 1 mL of serum. The sensitivity of the method was comparable to that for existing PCR techniques and could be parallelized to quantitatively detect multiple miRNA-based biomarkers in different biological samples. A novel assay that simultaneously detects multiple miRNAs within a single capillary by combining a tandem adenosine-tailed DNA bridge-assisted splinted ligation with denaturing capillary gel electrophoresis using laser-induced fluorescence was developed [41] . This CE-LIF assay not only represented a significant improvement in resolution but also allowed for the detection of multiple miRNAs within a single capillary based on the length differences of specified target bridge DNA. Five miRNAs of Epstein-Barr virus (EBV) were detected in EBV-infected nasopharyngeal carcinoma cells.In addition, the screening of isomer of miRNA (isomiRs) of BART2 was feasible with CE-LIF, indicating that this method is fast, amplification-free, multiplexed and cost-effective, making it potentially applicable to large-scale screening of isomiRs. Ban E et al. [42] developed CE-LIF for determination of low abundance miRNA-499, a biomarker candidate for acute myocardial infarction. The hybridized miRNA-499 was detected in cultured 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript enhance the effect of paclitaxel-induced apoptosis, suggesting that methylation of BLU may be a potential prognostic biomarker for advanced ovarian serous carcinoma [45].
Detection of cancer-associated virus
Human papillomavirus (HPV) E6/E7 type-specific oncogenes are required for cervical carcinogenesis. Current PCR protocols for genotyping high-risk HPV in cervical screening are not standardized and usually use consensus primers targeting HPV capsid genes, which are often deleted in neoplasia. PCR fragments are detected using specialized equipment and extra steps, 
Analysis of metabolic profiles of nucleosides

Diagnosis based on stored tissue and nucleic samples
The understanding and treatment of human cancer is currently undergoing a major transformation, propelled by the emergence of new genomic technologies, particularly tissue-based RNA and DNA microarrays. This so-called genomic revolution aims to capture the 
Application for cancer therapy
To the best of our knowledge, most cancers in the middle and advanced stages are difficult to cure. However, because genetic changes occur ahead of the phenotype, therapy based at a genetic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript level takes advantage of early discovery and affords a more accurate, targeted therapy.Thus, CE used for nucleic acid detection offers the advantages of high-sensitivity, high-speed and high-throughput and may be applied to effective cancer therapy as follows and discussed below: detecting cancer therapy-related gene polymorphisms and mutations;determining drug therapy influences on the immune system;studying the effects of anticancer agents;aiding in the discovery of new cancer therapy targets; and developing prognostic measures of cancer therapy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript sequencing [56] .However, the investigators did not observe any role for EGFR, KRAS and PIK3CA mutations in the prediction of EGFR-TKIs efficacy in patients.
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Detection of cancer therapy-related gene polymorphisms and mutations
A genetic TA repeat length polymorphism in the UGT1A1 promoter affects UDP-glucuronosyltransferase (UGT1A1) expression levels with significant clinical implications.
The presence of 7 TA repeats is associated with lowered UGT1A1 expression and the mild hyperbilinrubinemia manifested in Gilbert's syndrome. Furthermore, cancer patients carrying this variant exhibit irinotecan-related toxicity and require lower doses of this chemotherapeutic agent compared with patients carrying the 6 TA repeat allele, which is very common.This,therefore, necessitates the development of a reliable means of detecting TA repeat length in the clinical laboratory to deliver better personalized therapy regimens. Hence, Abou Tayoun AN et al. [57] developed and validated a PCR-CE method for accurately determining TA repeat length and guiding irinotecan dosing decisions for cancer patients. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
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The identification of somatically acquired tumour mutations is increasingly important in the clinical management of cancer because the sensitivity of targeted drugs is related to the genetic makeup of individual tumours. Thus, mutational profiles of tumours can help prioritize anticancer therapy. Su Z et al. [62] developed two PCR-CE based methods(SNaPShot Assay and Triplex Sizing Assay) to detect DNA from more than 40 recurrent mutations in nine genes relevant to existing and emerging targeted therapies in lung cancer.Their results showed that compared with direct sequencing, in which mutant DNA needs to compose 25% or more of the total DNA to easily detect a mutation, the PCR-CE methods could detect mutations in samples in which mutant DNA composed only 1.56% of the total DNA. These results should help accelerate adoption of a genotype-driven approach in the treatment of lung cancer.
The impact of a mutation in the ataxia telangiectasia mutated (ATM) gene in chronic lymphocytic leukaemia treatment outcome had not been examined before. Lozanski G et al. [63] studied ATM mutations in 73 patients treated with fludarabine and rituximab. The ATM gene mutation analysis was performed using temperature gradient CE. Their results indicated that truncating ATM mutations were rare in patients with chronic lymphocytic leukaemia .These non-silent variants also had limited impact on progression-free survival and overall survival.
Identification of chromosomal abnormalities is mandatory for classification of acute myeloid leukaemia (AML), and the abnormalities have to be determined quickly, to allow for patient enrolment in multicentre protocols or for selecting therapeutic strategies. Although Rapid AML molecular diagnosis is often difficult to achieve because it is based on numerous different RT-PCR protocols, a new RT-PCR-CE method to simultaneously detect all AML fusion transcripts from six major recurrent translocations was developed [64] , that obtained results in less than 24 hours,with a tumor cell detection threshold of 1.5%. Accumulation of methotrexate polyglutamates (MTX-(Glu)(n)) is a problem in MTX therapy.
SNP 452 C>T had been reported to associate with lower catalytic activity and higher accumulation of long-chain MTX-(Glu)(n) in patients treated with high doses of MTX. Cheng HL et al. [65] established an SSCP-CE method for detecting SNPs in the the γ-glutamyl hydrolase gene and found it was feasible for SNP screening.Polymorphisms in the 5' regulatory region of the thymidylate synthase gene have been shown to modulate thymidylate synthase expression and are associated with resistance to fluoropyrimidine-based therapies. Thomas F et al. [66] genotyped the thymidylate synthase gene 5'-UTR polymorphisms using PCR-RFLP-CE, which allowed identification of a 6-bp insertion in the 3R allele. The allelic frequencies for two uncommon polymorphisms in the TS gene (TYMS) promoter enhancer region (TSER) alleles were also found in the study.
Few studies have examined the prognostic implication of kinase domain mutations in patients
in the early chronic phase prior to imatinib-based therapy. Carella AM et al. [67] analysed the status of mutations in the samples collected at diagnosis from patients in the early chronic phase of chronic myeloid leukaemia (CML) using a direct sequencing (DS)-CE system. They found that kinase domain mutations conferred high-level imatinib resistance in patients with de novo CML and in some patients. This led to disease progression.
Drug therapy influences on the immune system
The immune systems of patients with multiple myeloma are suppressed by the disease itself,and this immunosuppression can be further exacerbated by standard therapies.An
RT-PCR-CE method was established to evaluate the effects of initial chemotherapy and a peripheral blood mobilisation regimen on T-cell population diversity [68] . 
Discovery of new cancer therapy targets
Anticancer chemotherapy is strongly hampered by the low therapeutic index of most anticancer drugs and the development of chemoresistance. Therefore, there is a continuous need It is reported that alterations in IKZF1, a transcriptional regulator of B lymphoid development, is associated with very poor outcomes in B-cell progenitor ALL. Therefore, Yang YL et al. [83] determined the prognostic significance of IKZF1 deletions in patients with childhood ALL using multiplex quantitative PCR-CE and high resolution melting.The results of their study indicated that detection of IKZF1 deletions upon diagnosis of B-cell progenitor ALL may help to identify patients at risk for treatment failure and that IKZF1 deletions could be incorporated as a new high-risk prognostic factor in future treatment protocols.
Limitations and future developments in the application of CE for nucleic acid detection
Many researchers have being attracted to CE analysis since it was developed, especially for the analysis of DNA [84] . However, CE has been used mostly in laboratory research rather than in clinical practice for more than 30 years. The application of CE to the analysis of nucleic acids appears to be hindered by six limitations. The first is that CE is a relatively new technique in Page 24 of 37 Analyst   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript analytical chemistry. Genetic diagnostics based on nucleic acid analysis is associated more with medicine and molecular biology. The combination of these two fields requires researchers knowledgeable in both subjects,but many scientists lack such a comprehensive background.The relatively low sensitivity of CE analysis is the second limitation in the field of DNA analysis [85] [86] . Except the double bond formed by the base group in DNA has a low ultraviolet-vis absorption, and a normal UV detector has a low sensitivity. The intrinsic low detection sensitivity drawbacks of CE, which are the limited light absorption dimension and the restricted sample injection length resulting in small sample injection volumes, also greatly restrain the application of DNA analysis by CE-UV. Consequently, fluorescence detection becomes the solution for sensitivity challenges of DNA analysis used by most researchers. However, this solution demands labeling samples with a fluorescence marker or intercalating dyes [87] , unfortunately this procedure is time-consuming,expensive, and most dyes are toxic (such as ethidium bromide
[EB]).In addition,the data derived from fluorescence detection electropherograms require integration with those from the more widely used UV electropherograms. Consequently, fluorescence detection has not yet achieved extensive application. Although CE performances have improve greatly over those in the preliminary stages of development, their stability and reproducibility are not as good as those provided by traditional techniques [88] [89] .Thus,the results derived from CE analyses still require verification by accepted methods like DGGE,direct sequencing,and real-time fluorescence quantitative PCR.This third limitation of CE that the technique is still under development and validation may be the reason that most of the diagnostic methods based on CE are not widely applied to clinical practice.The fourth and fifth limitations are that the equipments and reagents for CE are more expensive than other techniques and that necessary auxiliary equipments pre-existing in the clinic needs to be made compatibles with CE.This is a drawback especially when an automated identification system needs to be developed.The final limitation for the use of CE in clinical applications is that although MCE was developed many years ago, the high-efficiency, high-speed, microscale, automation and high-throughput advantages of this technique are not prominently known because the theory behind MCE is not yet mature and it has a relatively low automation.
On the other hand, the application of CE in clinical practice, has many advantages.The traditional methods for the separation of DNA are slab gel electrophoresis and the various types of Page 25 of 37 Analyst   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Analyst Accepted Manuscript affinity chromatography. Although these techniques enjoy wide-spread use in many laboratories, they suffer some intrinsic systematic disadvantages that have remain unsolved: (1) preparation and separation is time-consuming, taking at least 2 h,is labor-extensive and has a low efficiency; (2) sample elution and post-processing are difficult and often rely on the use of toxic and mutagenic reagents (such as EB and organic solvents),that may harm the health of operator;(3) the waste causes severe pollution. These issues are increasingly urgent when considering future applications in cancer diagnosis and therapy where speediness、safety and effectiveness are compulsory for medical needs. By contrast,the aforementioned shortcomings for analysis using CE may be offset by its higher resolution [90] , better sensitivity and reproducibility [91] ,rapidity,ease of use on a microscale and few harmful reagents.Moreover,CE can complete one detection in as little as a few minutes to dozens of minutes, so that hundreds of detections can be finished in a single day.
Even more detections can be acquired using MCE, meeting the need for a large number of clinical samples rapidly analysed.Although the equipments for CE may be relatively expensive, the operational costs are not because the consumed reagents are mainly water,inorganic salt, and a small amount of gel. Thus, after the investment of fixed assets,CE becomes cost-effective and has a great potential for use in the clinical diagnosis.
On the whole, although CE has limitations, many researchers are attracted by numerous advantages.Technique development is a process, and no technique is without limitations. Cures for most cancer pathologies have not yet been found, and an accurate and early diagnosis is essential for successful treatment.Thus,there is great potential for continued development of CE in the application of cancer diagnosis and therapy: The intrinsic drawback of sensitivity in CE may be overcome by combining it with other techniques, such as CE-ICP-MS [92] , or sample pre-concentration methods similar to that used in a report on the eletrokinetic stacking of DNA and proteins at an HF etched porous junction may be adopted [93] ; CE may also be combined with other methods offering additional benefits, such as CE-MS [94] ; Furthermore,the current advantages of speed,microscale and automation for MCE [95] [96] [97] [98] [99] [100] [101] [102] can be extended;
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